We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
Read MoreHide Full Article
Key Takeaways
Boston Scientific's EP sales jumped 63% in Q3, fueled by robust FARAPULSE-driven growth.
FDA approval expands BSX's FARAPULSE use to treat persistent atrial fibrillation patients.
Boston Scientific targets 50% PFA penetration by end-2025, rising to 80% globally by 2028.
Boston Scientific’s (BSX - Free Report) Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field Ablation (“PFA”) System, drove strong double-digit growth in the United States, where it was launched in 2024. Growth was also backed by the increasing adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now utilizing the integrated FARAWAVE NAV and OPAL device. Internationally, Japan and China also recorded a strong EP performance led by FARAPULSE.
FARAPULSE recently received the FDA’s approval for expanded labelling, with the system now able to be used for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation (AF). In the coming quarters, Boston Scientific aims to retain a strong leadership position in PFA, supported by an innovative portfolio, expanding mapping, commercial resources and consistent data publications. According to the company, global PFA penetration is expected to continue to expand and exit 2025 at 50% penetration and grow to approximately 80% by 2028.
Boston Scientific is investing to outpace the estimated 15% market growth through 2028 by advancing its ecosystem of innovative solutions across both the AF and non-AF segments. By late 2025, the company expects meaningful progress in expanding access to new technologies in more complex and redo patients with the launch of our FARAPOINT PFA catheter.
In addition, Boston Scientific will initiate enrollment in the OPTIMIZE trial, which will study the integration of OPAL in the Cortex AI algorithm. Cortex is a unique mapping software designed to precisely visualize and target sources of arrhythmias, addressing an unmet need in the treatment of persistent AF patients with unexplained recurrence.
BSX Peer Updates
Abbott’s (ABT - Free Report) EP sales increased 15.6% year over year in the third quarter of 2025, with double-digit sales growth in both the United States and internationally. The launch of Abbott’s new Volt PFA catheter in Europe continues to go very well and has helped deliver double-digit growth in ablation catheters and international markets. The company is preparing to Volt in the U.S. markets next year.
Medtronic (MDT - Free Report) is set to report second-quarter fiscal 2026 sales on Nov. 18. In the fiscal first quarter, the company’s Cardiovascular portfolio sales increased 7%, with cardiac ablation solutions growth accelerating to nearly 50%. This was driven by the strong uptake of Medtronic’s PFA system, including the PulseSelect anatomical catheter and the Sphere 9 focal catheter, and an Affera mapping system.
BSX Stock Performance, Valuation and Estimates
Year to date, Boston Scientific shares have risen 10.9% compared with the industry’s 0.6% growth.
Image Source: Zacks Investment Research
Boston Scientific is trading at a forward five-year Price-to-Earnings (P/E) of 29.16X compared with the industry average of 19.95X.
Image Source: Zacks Investment Research
See how Boston Scientific’s earnings have been revised over the past 90 days.
Image: Bigstock
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
Key Takeaways
Boston Scientific’s (BSX - Free Report) Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field Ablation (“PFA”) System, drove strong double-digit growth in the United States, where it was launched in 2024. Growth was also backed by the increasing adoption of the OPAL HDx mapping system, with one in three FARAPULSE accounts now utilizing the integrated FARAWAVE NAV and OPAL device. Internationally, Japan and China also recorded a strong EP performance led by FARAPULSE.
FARAPULSE recently received the FDA’s approval for expanded labelling, with the system now able to be used for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation (AF). In the coming quarters, Boston Scientific aims to retain a strong leadership position in PFA, supported by an innovative portfolio, expanding mapping, commercial resources and consistent data publications. According to the company, global PFA penetration is expected to continue to expand and exit 2025 at 50% penetration and grow to approximately 80% by 2028.
Boston Scientific is investing to outpace the estimated 15% market growth through 2028 by advancing its ecosystem of innovative solutions across both the AF and non-AF segments. By late 2025, the company expects meaningful progress in expanding access to new technologies in more complex and redo patients with the launch of our FARAPOINT PFA catheter.
In addition, Boston Scientific will initiate enrollment in the OPTIMIZE trial, which will study the integration of OPAL in the Cortex AI algorithm. Cortex is a unique mapping software designed to precisely visualize and target sources of arrhythmias, addressing an unmet need in the treatment of persistent AF patients with unexplained recurrence.
BSX Peer Updates
Abbott’s (ABT - Free Report) EP sales increased 15.6% year over year in the third quarter of 2025, with double-digit sales growth in both the United States and internationally. The launch of Abbott’s new Volt PFA catheter in Europe continues to go very well and has helped deliver double-digit growth in ablation catheters and international markets. The company is preparing to Volt in the U.S. markets next year.
Medtronic (MDT - Free Report) is set to report second-quarter fiscal 2026 sales on Nov. 18. In the fiscal first quarter, the company’s Cardiovascular portfolio sales increased 7%, with cardiac ablation solutions growth accelerating to nearly 50%. This was driven by the strong uptake of Medtronic’s PFA system, including the PulseSelect anatomical catheter and the Sphere 9 focal catheter, and an Affera mapping system.
BSX Stock Performance, Valuation and Estimates
Year to date, Boston Scientific shares have risen 10.9% compared with the industry’s 0.6% growth.
Image Source: Zacks Investment Research
Boston Scientific is trading at a forward five-year Price-to-Earnings (P/E) of 29.16X compared with the industry average of 19.95X.
Image Source: Zacks Investment Research
See how Boston Scientific’s earnings have been revised over the past 90 days.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.